Safety Study on Stopping Anticoagulation Medication in Patients With a History of Atrial Fibrillation (TACTIC AF)
August 11, 2020 updated by: Abbott Medical Devices
Pilot Study: Tailored Anticoagulation for Noncontinuous AF
The purpose of this study is to determine whether it is safe to stop anticoagulation medication in patients with a history of atrial fibrillation (AF) based on information from a pacemaker or implantable cardioverter defibrillator (ICD).
Study Overview
Status
Terminated
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
64
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
California
-
Los Angeles, California, United States, 90048
- Jeffrey Goodman, MD
-
-
Illinois
-
Chicago, Illinois, United States, 60611
- Northwestern Memorial Hospital
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02215
- Beth Israel Deaconess Medical Center
-
Boston, Massachusetts, United States, 02114
- Massachusetts General Hospital
-
-
Michigan
-
Lansing, Michigan, United States, 48912
- Sparrow Research Institute
-
-
New Jersey
-
Hackensack, New Jersey, United States, 76011
- Hackensack University Medical Center
-
-
Oregon
-
Corvallis, Oregon, United States, 97330
- Samaritan Heart and Vascular Institute
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, United States, 19107
- Jefferson Heart Institute
-
Pittsburgh, Pennsylvania, United States, 15212
- Allegheny Singer Research Institute
-
-
Texas
-
San Antonio, Texas, United States, 78229
- STAR Clinical Trials, LLC / Cardiology Clinic of San Antonio
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Patient has a St Jude Medial device that is compatible with Merlin.net (remote monitoring)
- Patient has history of atrial fibrillation (non-continuous)
- Patient must be taking a a blood thinner medication other than warfarin or aspirin for atrial fibrillation
- Patient is willing to complete a questionnaire
Exclusion Criteria:
- Patient is in atrial fibrillation all of the time
- Patient has a history of stroke or blood clot
- Patient is on warfarin or coumadin
- Patient cannot be taken off of his blood thinner medication due to another medical condition
- Patient is not capable of sending a remote device transmission to doctor once a week
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Basic Science
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
No Intervention: Control
Remote transmissions were scheduled per each institution's device monitoring protocol.
Anticoagulation was initiated/discontinued based on standard of care/guidelines as prescribed by doctor
|
|
|
Experimental: Tailored Anticoagulation (TAC)
Anticoagulation was initiated or discontinued based on atrial tachycardia / atrial fibrillation (AT/AF) burden as assessed through frequent remote transmissions via Merlin.net. Patients sent in biweekly remote transmissions, automatic alert-triggered transmissions for AT/AF burden above a set threshold, and unscheduled patient-activated transmissions as needed |
Patient will stop or restart drug per cardiac device information (AT/AF diagnostics for prespecified AT/AF episode duration per day and total burden).
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Total Cumulative Days on Anticoagulation
Time Frame: one year
|
To assess the reduction in time on anticoagulation, the cumulative total number of days on anticoagulation for each group throughout the follow-up period was determined.
This study was designed as a pilot/feasibility study and therefore was not powered to detect thromboembolic events.
Per study protocol, all patients completed a 30 day run-in period following enrollment during which anticoagulation could not be stopped regardless of AT/AF burden.
|
one year
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Peter Zimetbaum, MD, Beth Israel Deaconess Medical Center
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
January 1, 2013
Primary Completion (Actual)
December 1, 2016
Study Completion (Actual)
August 1, 2017
Study Registration Dates
First Submitted
July 23, 2012
First Submitted That Met QC Criteria
July 25, 2012
First Posted (Estimate)
July 26, 2012
Study Record Updates
Last Update Posted (Actual)
August 13, 2020
Last Update Submitted That Met QC Criteria
August 11, 2020
Last Verified
August 1, 2020
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 60039204/C
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.